Drugs / Cardonilizumab
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06363006 | Mar 2024 → Jan 2026 overdue | hepatocellular carcinoma | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05994001 | Aug 2023 → May 2026 overdue | biliary tract cancer | Shanghai Zhongshan Hospital | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06421376 | May 2024 → Dec 2026 expected | esophageal squamous cell carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07699185 | Jan 2024 → Jul 2026 overdue | esophageal squamous cell carcinoma | Tongji Hospital | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cardonilizumab | “Cardonilizumab was administered every 2 weeks on the first day of each cycle for up to 24 months” NCT06363006 ↗ |
| Route | Intravenous | “Cardonilizumab will complete infusion within 60 minutes (± 10 minutes)” NCT06363006 ↗ |